Although previous studies reveal that TNFR2 is the main TNFR expressed by B and T lymphocytes in breast cancer draining lymph nodes (dLNs) (Ghods et al., 2019), and TNFR2 is implicated in the progression and prognosis of breast cancer (Yang et al., 2017), there is no direct evidence that targeting TNFR2 can benefit breast cancer treatment. This evidence concerns the gene TNFRSF1A and breast cancer.